Enhertu

navigating-the-loss-of-exclusivity

Jun 13, 2025

Navigating the Loss of Exclusivity: Big Pharma’s New Playbook

enhertu-for-cancer-treatment-and-management

May 09, 2025

ENHERTU’s Rapid Rise: How the HER2-Targeting ADC Is Redefining Cancer Treatment with Back-to-Back Label Expansions

antibody-drug-conjugates-adcs-in-lung-cancer-treatment

May 09, 2025

ADCs in Lung Cancer Treatment: ENHERTU’s Rise, HER3 & TROP-2 Challenges, and What’s Next in the Pipeline

roches-her2-positive-breast-cancer-therapies

Aug 13, 2024

Roche’s HER2-Positive Breast Cancer Treatment Franchise

enhertu-for-her2-positive-solid-tumors

Apr 15, 2024

ENHERTU: Another Triumph to Celebrate for AstraZeneca and Daiichi Sankyo

pharma-news-for-astrazeneca-daiichi-sankyo-basilea-genmab

Apr 09, 2024

AstraZeneca and Daiichi Sankyo’s Enhertu US Approval; Basilea’s ZEVTERA FDA Approval; Genmab’s ProfoundBio Acquisition; Rocket Pharmaceuticals’ RP-L102 EMA Approval; Alexion’s Ultomiris and Soliris AAN 2024 Data

Pharma News for Merck, BMS, Sanofi, Juvena

Jan 30, 2024

Merck’s KEYTRUDA as Adjuvant Therapy for RCC Patients; BMS Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma for Multiple Myeloma; FDA Approves Dupixent for Eosinophilic Esophagitis; Juvena Receives FDA Orphan Drug Designation for JUV-161; European Commission Authorizes GSK’s Omjjara; ENHERTU Granted Priority Review in the US for for metastatic HER2-positive Solid Tumors

antibody-drug-conjugates-adcs-in-oncology

Jun 02, 2023

Antibody-drug Conjugates in Oncology: An Overview of the Current and Future Treatment Landscape

top-10-oncology-drugs-launches-2023

Feb 24, 2023

Top 10 Expected Oncology Drug Launches in 2023

latest-pharma-news-and-updates-for-eli-lilly-novartis-janssen-ipsen-kite

Jan 31, 2023

Eli Lilly’s Jaypirca Approval; Novartis’ Adakveo EMA Review; Janssen’s CARTITUDE-4 Study of CARVYKTI; Negative Review on Ipsen’s Palovarotene; Gilead Sciences and Kite’s Yescarta NICE Recommendations; Daiichi Sankyo and AstraZeneca’s Enhertu EU Approval

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper